BLAINTRAVENOUSVIALPriority Review
Approved
May 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Mechanism of Action
CD52-directed Antibody Interactions
Pharmacologic Class:
CD52-directed Cytolytic Antibody
Indications (1)
Clinical Trials (5)
TMLI and Alemtuzumab for Treatment of Sickle Cell Disease
Started Jul 2022
Effect of Alemtuzumab on Microglial Activation Positron Emission Tomography (PET) in Multiple Sclerosis
Started Dec 2021
0Multiple Sclerosis
Immune Response to COVID-19 Vaccine in Multiple Sclerosis Patients Treated With Teriflunomide and Alemtuzumab
Started Mar 2021
70 enrolled
Multiple Sclerosis
Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab
Started Sep 2020
6 enrolled
B-Cell Prolymphocytic LeukemiaChronic Lymphocytic LeukemiaPeripheral T-Cell Lymphoma+3 more
CAMPath and BELimumab for Transplant Tolerance in Sensitized Kidney Transplant Recipients
Started May 2019
3 enrolled
Kidney Transplantation